ReproNovo is a biopharmaceutical company focused on developing treatments for reproductive medicine and women’s health. Its lead clinical compound, RPN-001 (leflutrozole), is being developed to treat male infertility, while RPN-002 (nolasiban) is designed to manage adenomyosis and improve embryo implantation in ART. Both assets are Phase 2 ready. The company intends to use the Series A proceeds to advance a pipeline of multiple Phase 2 programs. ReproNovo is led by CEO Jean Marie Duvall, CSO & CMO Joan‑Carles Arce, MD, PhD, and CFO BingMei Hao. It maintains a primary development team in Copenhagen and an additional development site in Barcelona, with corporate base in Lausanne, Switzerland.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

May 2025